meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
es-BC - TNBC - NA - all population
5
es-BC - TNBC - NA - PDL1 positive
1
es-BC - Triple negatif (TNBC) - 1st line (L1)
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1)
1
mBC - TNBC - L1 - all population
7
mBC - TNBC - L1 - PDL1 positive
4
mBC-Triple negative (TNBC) - 2nd Line (L2)
3
mBC - TNBC - L2 - all population
2
mBC - TNBC - L2 - PDL1 positive
2
All treatments
AKT inhibitor
capivasertib based treatment
capivasertib plus paclitaxel
ipatasertib based treatment
ipatasertib plus paclitaxel
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus nab-paclitaxel
atezolizumab plus paclitaxel
pembrolizumab based treatment
pembrolizumab plus SoC
poly ADP-ribose polymerase (PARP) inhibitor
veliparib plus paclitaxel plus carboplatin
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
summary
GRADE
treatment
patients
risk of bias
overview
numeric
bar chart
forest plot
medians
frequency on treatment
benefit risk analysis
Study
study type
RCT
OBS
RCT + OBS
Pathology
T1
T0
Patients
sample sizes
ROB
Results
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open